STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...
News-Medical.Net on MSN
Tufts researchers identify new vulnerabilities to combat persistent C. diff infections
Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile —commonly known as C. diff —are a serious and persistent problem for patients and ...
Clostridioides difficile/Clostridium difficile (C. diff) is a bacterial infection and is the most common cause of healthcare-associated diarrhea. C. diff has two distinct presentations, primary and ...
Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and ...
The portion of our nervous systems responsible for the 'fight or flight' response can shape the severity of potentially deadly C. difficile infections, according to new research. The portion of our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results